-

908 Devices to Participate in the Gilmartin Group Emerging Growth Company Showcase

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the upcoming Gilmartin Group Emerging Growth Company Showcase.

908 Devices’ management is scheduled to present on Thursday, September 21 at 9:00 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Contacts

Media Contact
Barbara Russo
brusso@908devices.com

Investor Contact
Carrie Mendivil
IR@908devices.com

908 Devices Inc.

NASDAQ:MASS

Release Versions

Contacts

Media Contact
Barbara Russo
brusso@908devices.com

Investor Contact
Carrie Mendivil
IR@908devices.com

More News From 908 Devices Inc.

908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and Mitigation

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces a $2M order from the Texas Department of Public Safety for its MX908 handheld mass spectrometry device. This investment in advanced tools for drug detection builds on an initial order placed last year for several MX908 devices, and is funded through the Community Oriented Policing Services (COPS) grant, a federally funded, state-administered program. The MX908 p...

908 Devices Announces Preliminary First Quarter 2025 Financial Results

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for safety and defense tech applications, today announced preliminary unaudited financial results for the quarter ended March 31, 2025. Preliminary unaudited revenue from continuing operations for the first quarter of 2025 is expected to be at least $11.5 million, compared to $7.4 million of revenue from continuing operations in the first quarter of...

908 Devices Receives $1.7M Order from the Ministry of Health of Ukraine for its Handheld Mass Spec Device

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer in purpose-built handheld devices for chemical analysis, announces that it has received a $1.7 million order from the Ministry of Health of Ukraine for its MX908 handheld mass spectrometry device with Aero module for priority shipment in the first quarter 2025. The devices will be part of an environmental testing kit in a post-war environment and will be used primarily to detect and identify trace substances of hazardous materi...
Back to Newsroom